Antifungal management: the key factors for making an informed decision
16 May 2009, 13.30-15.30
Integrated symposium arranged by Gilead Sciences. The opinion of the speakers is not necessarily congruent with that of ESCMID.
- Chairpersons: J. Maertens (Leuven, BE), M. Richardson (Helsinki, FI)
Welcome and opening remarksWhat are you dealing with? - C. Lass-Flörl (Innsbruck, AT)
The evolution of fungal epidemiology - C.P. Heussel (Heidelberg, DE)
What are you looking at? The use of high-resolution CT scanning in presumed fungal infections - M. Richardson (Helsinki, FI)
What are your choices? Translating the broad-spectrum, fungicidal properties of AmBisome into clinical practice - S. Agrawal (London, UK)
What are the issues? The pros and cons of different anti-fungal agents - Chairpersons
Symposium summary and close
New frontiers in serious Gram-positive infections
17 May 2009, 9.00-11.00
Integrated symposium arranged by Novartis. The opinion of the speakers is not necessarily congruent with that of ESCMID.
- Chairpersons: Robert Skov (Copenhagen, DK), Roland Leclercq (Caen, FR)
- R. Skov (Copenhagen, DK)
Introduction - E. Bouza (Madrid, ES)
Defining new frontiers - M.J. Rybak (Detroit, US)
Managing cost in hospital infections - R.A. Seaton (Glasgow, UK)
OPAT in Europe: the next frontier? - Questions and panel discussion
- R. Skov (Copenhagen, DK)
Conclusion
